Investor Presentaiton
Immunology
LPA₁
Sotyktu
CD19 NEX T
First-in-class TYK2 inhibitor to treat PsO, with broad
potential across PsA, SLE, SjS, and AA
Today
Psoriasis
Sotyktu is approved for
moderate-to-severe PSO and has
reset the bar for oral treatments
Near-Term
Psoriatic
Arthritis
Leveraging strong relationship
between PSO and PsA, sharing
common pathogenic mechanisms1
Future
Systemic Lupus Erythematosus,
Sjögren's Syndrome, &
Alopecia Areata
Disruptive potential in SLE
and new opportunity in SjS
given similar disease pathogenesis
Potential in AA based on inhibition of
the IL-12/IFNY axis²
Oral, tolerable, mechanistically differentiated TYK-2 targeting
agent provides broad applicability across a range of immune-mediated diseases
1. Mease PJ, Armstrong AW. Drugs. 2014;74:423-441. 2. Edelkamp J, et al. ESDR 2022 [poster presentation].
Bristol Myers Squibb™
Not for Product Promotional Use
67View entire presentation